You are here: Home » Companies » News
Business Standard

Astrazeneca gets nod to use ant-diabetes drug for kidney disease in India

The firm said it has received marketing authorisation to use its anti-diabetic drug dapagliflozin for the treatment of patients with chronic kidney disease

Topics
AstraZeneca | Pharma sector | kidney disease

Press Trust of India  |  New Delhi 

AstraZeneca
AstraZeneca. Photo: Reuters

Drug firm India on Monday said it has received marketing authorisation to use its anti-diabetic drug dapagliflozin for the treatment of patients with chronic (CKD).

The receipt of the permission paves way for the launch of dapagliflozin tablets (10 mg) in the country to treat CKD, the company said in a statement.

The drug is the first medicine in SGLT-2i class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with CKD, it added.

The study results of dapagliflozin showed significant benefits in reducing CKD progression in patients with and without type-2 diabetes.

"Despite currently available therapies, a significant unmet need for effective management of CKD continues to exist globally. With the approval of dapagliflozin for CKD in India, an already effective type-2 diabetes and select heart failure treatment, can now be used by nephrologists in the management of CKD," India Vice President - Medical Affairs and Regulatory Anil Kukreja said.

CKD is an emerging public health problem. The global disease burden report of 2015 pointed that CKD is the 12th most common cause of death with a 37.1 per cent rise in mortality over 10 years.

It is a serious, progressive condition defined by decreased kidney function and kidney damage, affecting nearly 70 crore people worldwide, many of them still undiagnosed.

The prevalence of CKD in India is estimated to be 17.2 per cent, given its 1 billion plus population, the rising incidence of CKD is likely to pose major problems for both healthcare and the economy in future years.

CKD is associated with significant patient death and an increased risk of cardiovascular (CV) events, such as heart failure and premature death. While there are medications that can address some of the risk factors for CKD or its associated problems, few work directly to slow renal disease progression.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 08 2021. 14:45 IST
RECOMMENDED FOR YOU